AU Patent

AU2015309862A1 — High-purity quinoline derivative and method for manufacturing same

Assigned to Eisai R&D Management Co Ltd · Expires 2017-03-02 · 9y expired

What this patent protects

Provided is a compound represented by formula (IV) or a salt thereof, said compound containing no more than 350 mass ppm of the compound represented by formula (I).

USPTO Abstract

Provided is a compound represented by formula (IV) or a salt thereof, said compound containing no more than 350 mass ppm of the compound represented by formula (I).

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

Patent Metadata

Patent number: AU2015309862A1
Jurisdiction: AU
Classification: —
Expires: 2017-03-02
Drug substance claim: No
Drug product claim: No
Assignee: Eisai R&D Management Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.